[go: up one dir, main page]

WO2018198135A1 - Procédé amélioré pour la préparation d'un complexe de fer - Google Patents

Procédé amélioré pour la préparation d'un complexe de fer Download PDF

Info

Publication number
WO2018198135A1
WO2018198135A1 PCT/IN2018/050250 IN2018050250W WO2018198135A1 WO 2018198135 A1 WO2018198135 A1 WO 2018198135A1 IN 2018050250 W IN2018050250 W IN 2018050250W WO 2018198135 A1 WO2018198135 A1 WO 2018198135A1
Authority
WO
WIPO (PCT)
Prior art keywords
iron
dextran
sodium
iii
solution
Prior art date
Application number
PCT/IN2018/050250
Other languages
English (en)
Inventor
Sureshbabu JAYACHANDRA
Sonny Sebastian
Jayaprakash Thirunavukarasu
Rajakrishna Yerramalla
Jaganmohanarao BONTALAKOTI
Original Assignee
Mylan Laboratories Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mylan Laboratories Ltd. filed Critical Mylan Laboratories Ltd.
Publication of WO2018198135A1 publication Critical patent/WO2018198135A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • C08B37/0006—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid
    • C08B37/0009—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid alpha-D-Glucans, e.g. polydextrose, alternan, glycogen; (alpha-1,4)(alpha-1,6)-D-Glucans; (alpha-1,3)(alpha-1,4)-D-Glucans, e.g. isolichenan or nigeran; (alpha-1,4)-D-Glucans; (alpha-1,3)-D-Glucans, e.g. pseudonigeran; Derivatives thereof
    • C08B37/0021—Dextran, i.e. (alpha-1,4)-D-glucan; Derivatives thereof, e.g. Sephadex, i.e. crosslinked dextran
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F15/00—Compounds containing elements of Groups 8, 9, 10 or 18 of the Periodic Table
    • C07F15/02—Iron compounds
    • C07F15/025—Iron compounds without a metal-carbon linkage

Definitions

  • the present invention relates to an improved process for the preparing Iron complexes. BACKGROUND OF THE INVENTION
  • Iron is important for many functions in the body, especially for the transport of oxygen in the blood. Those suffering from iron deficiencies often require external supplementation of this vital mineral.
  • iron dextran is a complex of ferric oxide and dextran, and has been known for about 35 years. Iron dextran is used to treat iron deficiencies and iron deficiency anemia.
  • US2885393 first disclosed a basic process for the preparation of iron dextran complex in which the average molecular weight of the dextran is 30,000 to 80,000 Daltons (Da) or lower.
  • supplemental iron is sodium ferric gluconate, chemically known as D-gluconic acid iron sodium salt.
  • Sodium ferric gluconate complex is approved under the trade name Ferrlecit by the United States Food and Drug Administration (USFDA).
  • USFDA United States Food and Drug Administration
  • Sodium ferric gluconate complex is an intravenously administered iron product indicated in the treatment of iron deficiency anemia. It is frequently used in patients undergoing hemodialysis, those undergoing erythropoietin therapy, and/or patients who have chronic kidney disease. US7179939 which is incorporated here for reference, disclosed process for the preparation of sodium ferric gluconate.
  • the present invention provides an improved process that is stable, reproducible, easy to prepare on an industrial scale, and consistent in quality and molecular weight range.
  • the present invention relates to an improved process for the preparation of Iron complexes.
  • the present invention relates an improved process for the preparation of stable ferric oxy hydroxide.
  • the present invention relates to an improved process for the preparation of Iron dextran. a) reacting water soluble of iron (III) salt with an inorganic base
  • the present invention relates to a one stage process for the preparation of Sodium ferric gluconate. a) reacting water soluble of iron (III) salt with an inorganic base
  • the present invention provides an improved process for the preparation of Iron complexes.
  • the present invention provides an improved process for the preparation of Iron dextran comprising the steps of: a) reacting a water-soluble iron (III) salt with an inorganic base
  • Iron dextran may be prepared by reacting a water-soluble salt of iron(III) with an inorganic base in water.
  • suitable water-soluble salts of iron(III) include iron(III) bromide, iron(III) chloride, iron(III) iodide, iron(III) nitrate, iron(III) sulfate, or any solvates thereof (e.g., iron(III) chloride hexahydrate).
  • suitable inorganic bases include any that facilitate the formation of iron(III) hydroxide, for example, sodium carbonate, sodium hydroxide, potassium hydroxide, and lithium hydroxide.
  • an aqueous iron(III) chloride hexahydrate solution is added to an aqueous sodium carbonate solution to form an iron(III) hydroxide solution.
  • oxidized dextran may be added which is optionally purified.
  • the dextran may have an average molecular weight of about 5000 daltons to about 10000 daltons.
  • the pH of the reaction mass may be adjusted to 10 - 13 using a base. This adjustment may be carried out using methods well known by those skilled in the art (i.e., using appropriate acid or base).
  • the reaction mass may then be heated, for example, to 90-100°C, and maintained at an elevated temperature for an extended period of time, for example, for about 2 hours.
  • iron dextran may be isolated. This may be carried out by methods well known by one of skill in the art. For example, in some embodiments, precipitation of the iron dextran may be facilitated by cooling the reaction mixture and adding methanol. The precipitated solid may be isolated by filtering the reaction mixture then optionally dried to obtain the desired product.
  • Iron dextran can be isolated by initially adjusting the pH of the reaction mixture which is cooled after heating and spray dried.
  • the present invention provides an improved process for the preparation of Iron dextran comprising the steps of: a) reacting a water-soluble iron (III) salt with an inorganic base
  • Iron dextran may be prepared by reacting a water-soluble salt of iron(III) with an inorganic base.
  • suitable water-soluble salts of iron(III) include iron(III) bromide, iron(III) chloride, iron(III) iodide, iron(III) nitrate, iron(III) sulfate, or any solvates thereof (e.g., iron(III) chloride hexahydrate).
  • suitable inorganic bases include any that result in the formation of iron(III) hydroxide, for example, sodium carbonate, sodium hydroxide, potassium hydroxide, and lithium hydroxide.
  • an aqueous iron(III) chloride hexahydrate solution is added to an aqueous sodium carbonate solution to form an iron(III) hydroxide solution.
  • oxidized dextran may be added.
  • the dextran may have an average molecular weight of about 5000 daltons to about 10000 daltons.
  • the pH of the reaction mass may be adjusted to 10 - 13 using a base. This adjustment may be carried out using methods well known by those skilled in the art (i.e., using appropriate acid or base).
  • the reaction mixture may be cooled and the pH adjusted to 4-5 (using appropriate acid such as hydrochloric acid) and optionally purified.
  • the Purification can be carried out by methods well known in the art, for example, by ultrafiltration, diafiltration, ion exchange, dialysis, or any combination thereof.
  • filtration is carried out by ultrafiltration.
  • maintaining the reaction mixture before undertaking subsequent steps for about 1-2 hours is particularly useful.
  • a second lot of dextran [may be oxidized or reduced] may then be added to the purified solution and the temperature may be optionally adjusted to 60-80 °C and maintained at that temperature for an extended period of time, e.g., for about 3-4 hours.
  • the second lot of dextran added may be oxidized dextran, reduced dextran, or a mixture of oxidized and reduced dextran.
  • the second lot of dextran may have an average molecular weight of about 5000 Daltons to about 10000 Daltons.
  • iron dextran may be isolated, for example, by removal of the solvent or by causing precipitation of the iron dextran compound.
  • Methods well known by one of skill in the art e.g., distillation, spray drying, freeze drying may be used to carry out this isolation step.
  • Oxidized dextran may be prepared by methods well known in the art. For example, an aqueous solution of dextran and sodium hydroxide and may be combined with an aqueous solution of sodium hypochlorite. In some embodiments, this reaction is carried out for about 6 hours.
  • Reduced dextran may be prepared by methods well known in the art. For example, an aqueous solution of dextran and sodium hydroxide may be combined with sodium borohydride dissolved in dilute sodium hydroxide. In some embodiments, this reaction is carried out for about 3-4 hours. Isolation of the reduced dextran may be carried out by methods well known in the art, for example, by filtering the solution and adding methanol to form a solid. The solution may then be filtered to obtain a solid, which may be optionally dried to obtain the desired product.
  • the present invention provides an improved process for the preparation of sodium ferric gluconate, which includes the following steps: a) reacting an aqueous solution iron(III) chloride hexahydrate with an inorganic base b) adding a second base
  • sodium ferric gluconate may be prepared by first reacting an aqueous solution of iron(III) chloride hexahydrate with an inorganic base.
  • suitable inorganic bases include sodium bicarbonate, potassium bicarbonate, lithium bicarbonate, ammonium bicarbonate, sodium hydroxide, potassium hydroxide, lithium hydroxide, rubidium hydroxide, cesium hydroxide, and mixtures thereof.
  • sodium hydroxide is used as the inorganic base.
  • a second base may be added to the reaction mixture, followed by addition of a derivative of gluconic acid.
  • the reaction mixture is maintained for some time, e.g., 2-3 hours, before addition of the gluconic acid derivative.
  • suitable gluconic acid derivatives include alkali earth metal salts of gluconic acid. In particularly useful embodiments, sodium gluconate is used.
  • the reaction mixture may then be heated. In some embodiments, heating the reaction mixture to a temperature of about 100°C may be particularly useful. In some embodiments, maintaining the reaction mixture at this elevated temperature for about 4 to about 6 hours may be particularly useful.
  • the reaction mixture may be cooled and the pH may be adjusted to about 6 to about 9 using methods well known in the art (i.e., addition of an acid or a base). In particularly useful embodiments, the pH is adjusted to about 7 to about 8.
  • the reaction mixture may optionally be purified. Purification can be carried out by methods well known in the art, for example, by diafiltration, ultrafiltration, ion exchange, dialysis, or any combination thereof. In particularly useful embodiments, filtration is carried out by ultrafiltration. In some embodiments, maintaining the reaction mixture before undertaking subsequent steps for about 1-2 hours is particularly useful.
  • sodium ferric gluconate may then be isolated.
  • sodium ferric gluconate may be isolated by methods well known in the art.
  • precipitation may be initiated by the addition of an anti-solvent
  • ethanol is found to be a particularly useful anti-solvent while acetone and methanol can also be used as anti-solvents.
  • the precipitated solid may be isolated by filtration and dried to obtain the desired product.
  • the solid formed is filtered and washed with an alcoholic solvent preferably ethanol to obtain sodium ferric gluconate complex.
  • the present invention provides an improved process for the preparation of sodium ferric gluconate comprising the steps of a) reacting water soluble of iron (III) salt with an inorganic base
  • sodium ferric gluconate may be prepared by first reacting an aqueous solution of iron(III) chloride hexahydrate with an inorganic base.
  • suitable inorganic bases include sodium bicarbonate, potassium bicarbonate, lithium bicarbonate, ammonium bicarbonate, sodium hydroxide, potassium hydroxide, lithium hydroxide, rubidium hydroxide, cesium hydroxide, and mixtures thereof.
  • sodium hydroxide is used as the inorganic base.
  • a second base may be added to the reaction mixture, followed by addition of a derivative of gluconic acid.
  • the reaction mixture is maintained for some time, e.g., 2-3 hours, before addition of the gluconic acid derivative.
  • suitable gluconic acid derivatives include alkali earth metal salts of gluconic acid.
  • sodium gluconate is used.
  • sucrose may also be added.
  • the reaction mixture may then be heated. In some embodiments, heating the reaction mixture to a temperature of about 100°C may be particularly useful. In some embodiments, maintaining the reaction mixture at this elevated temperature for about 4 to about 6 hours may be particularly useful. Next, the reaction mixture may be cooled and, if needed, the pH may be adjusted to about 6 to about 9 using methods well known in the art (i.e., addition of an acid or a base). In particularly useful embodiments, the pH is adjusted to about 7 to about 8.
  • the reaction mixture may optionally be purified. Purification can be carried out by methods well known in the art, for example, by diafiltration, ultrafiltration, ion exchange, dialysis or any combination thereof. In particularly useful embodiments, filtration is carried out by ultrafiltration. In some embodiments, maintaining the reaction mixture before undertaking subsequent steps for about 1-2 hours is particularly useful.
  • a second lot of gluconic acid derivative may then be added. After adding the second lot of gluconic acid derivative, the pH may be adjusted to about 9 - 10.
  • sodium ferric gluconate may be isolated by methods well known in the art.
  • precipitation may be initiated by the addition of an anti-solvent, for example an alcohol.
  • suitable alcohol anti-solvents include ethanol, methanol, or mixtures thereof.
  • ethanol is found to be a particularly useful anti-solvent while acetone and methanol can also be used as anti-solvents.
  • the precipitated solid may be isolated by filtration and optionally dried to obtain the desired product.
  • processes disclosed herein may have the following advantages over prior art: a) One stage process for preparing iron complexes.
  • Example-1 A mixture of Ferric chloride hexahydrate (100 g, 0.369 mole) in water (1000 ml) was stirred at room temperature for 10-20 minutes. Sodium carbonate solution (56 g, 0.528 mole) in water (200ml) was added to mixture at 25-35°C in lot wise and stirred for 110-120 minutes. Sodium hydroxide solution (6 g, 0.15 mole) in water (50ml) was added to reaction mixture and stirred for 1-2 hours. A solution of Sodium gluconate (40 g, 0.183 mole) was added to the mixture followed by water (50ml) and heated to 98-100°C and stirred for 4-6 hours.
  • Example - 3 A solution of Ferric chloride hexahydrate (100 g, 0.369 mole) in water (1000 ml) was mixed with a solution of Sodium carbonate solution (56 g, 0.528 mole) in water (200ml) and stirred at room temperature for 110-120 minutes. The resulting solid was collected by filtration and washed with water (1000ml). Above obtained solid was mixed water (600 ml) and stirred with sodium hydroxide solution (6 g, 0.15 mole) in water (50ml) and stirred 1-2 hours. Sodium gluconate (40 g, 0.183 mole) and water (50ml) were added to the mixture and heated to 98-100°C for 4-6 hours and cooled to room temperature.
  • Example-4 Sodium carbonate solution (56 g, 0.528 mole) in water (200ml) was added in lot wise to a mixture of Ferric chloride hexahydrate (100 g, 0.369 mole) in water (1000 ml) was stirred at room temperature for 10-20 minutes and further stirred for 1-2 hours.
  • Sodium hydroxide solution (6 g, 0.15 mole) in water (50ml) was charged to reaction mixture followed by Sodium gluconate (40 g, 0.183 mole) and sucrose (300g, 0876 moles). The mixture was heated to 98-100°C and maintained for 4-6 hours. Reaction mixture was cooled to room temperature and adjusted in between pH-7.0- 8.0. The solution was filtered by ultrafiltration using membrane.
  • Example- 5 A mixture of Dextran-5 (Average Molecular weight 5000) (100 g, 0.02 mole) and sodium hydroxide (0.5 g, 0.01 mole) in water was stirred at room temperature at RPM 30-50 for 30 minutes. Sodium hypo chlorite solution ( 100 ml, 0.15 mole) was added to the mixture. The reaction mixture was stirred at room temperature for 6 hours. A solution of sodium carbonate (24 g, 0.2264 mole) in water (100 ml) was added a solution of Ferric chloride hexahydrate (100 g, 0.369 mole) and water (500 ml) and the resulting reaction mass was added to the above reaction mixture.
  • Dextran-5 Average Molecular weight 5000
  • sodium hydroxide 0.5 g, 0.01 mole
  • dextran- 5 (Average Molecular weight 5000) (100 g, 0.02 mole) and sodium hydroxide (0.5 g, 0.01 mole) in water was stirred at room temperature for 30 minutes.
  • Sodium hypo chlorite solution (100 ml, 0.15 mole) was added mixture.
  • the reaction mixture was stirred at room temperature for 6 hours.
  • the solution was purified using membrane process (dia filtration).
  • Another mixture of Ferric chloride hexahydrate (100 g, 0.369 mole) and water (500 ml) a solution of sodium carbonate (24 g, 0.2264 mole) in water ( ml) and stirred for 10-20 minutes (RPM 80- 100).
  • This reaction mixture was mixed with above prepared reaction mass and basified with sodium hydroxide solution.
  • the obtained mixture was heated at 95°C for 2 hours and cooled to an ambient temperature and acidified pH 4-5 using Hydrochloric acid.
  • the solution was purified using membrane process (dia filtration). The solution was spray dried to get Iron Dextran powder.
  • Example-7 A mixture of dextran -5 (Average Molecular weight 5000) (100 g, 0.02 mole) and sodium hydroxide (0.5 g, 0.01 mole) in water was stirred (RPM 30-50) at room temperature for 30 minutes. Sodium hypo chlorite (100 ml, 0.15 mole) was added mixture. The reaction mixture was stirred at room temperature for 6 hours. The solution was purified using membrane process (dia filtration). Another mixture of Ferric chloride hexahydrate (100 g, 0.369 mole) was dissolved water (500 ml) and added a solution of sodium carbonate (24 g, 0.2264 mole) in water to it and stirred for 15-20 minutes (RPM 80-100).
  • This reaction mass was mixed with above obtained Dextran reaction mass and the resulting mixture was basified with a solution of sodium hydroxide.
  • the obtained mixture was heated at 95 -100 °C for 2 hours and cooled to an ambient temperature and acidified pH 4-5 using Hydrochloric acid. Solution was concentrated by distillation to a volume 650 ml and then stirred with methanol. The resulting crystalline solid was collected by filtration and washed with methanol. The obtained solid was dried under vacuum to get Iron Dextran.
  • Example-8 A mixture of dextran -5 (Average Molecular weight 5000) (100 g, 0.02 mole) and sodium hydroxide (1.0 g, 0.02 mole) in water was stirred at room temperature for 30 minutes. Sodium hypochlorite (50ml, 0.075 mole) was added and stirred at room temperature for 6 hours. The solution was purified using membrane process (dia filtration). Another mixture of Ferric chloride hexahydrate (100 g, 0.369 mole) and water (500 ml) was mixed with a solution of sodium carbonate (24 g, 0.2264 mole) in water and added to the above obtained Dextran reaction mass. To the resulting mixture added a solution of sodium hydroxide to attain basic pH.
  • the obtained mixture was maintained at 95-100°C for 120 minutes and cooled to an ambient temperature and acidified to pH4-5 using Hydrochloric acid. Solution was concentrated to a volume 650 ml and then added to methanol with stirring. The resulting crystalline solid was collected by filtration and washed with methanol. The obtained solids were dried under vacuum to get iron dextran solids.
  • a mixture of dextran-5 (Average Molecular weight 5000) (100 g, 0.02 mole) and sodium hydroxide (1.0 g, 0.02 mole) in water was stirred at room temperature for 30 minutes.
  • Sodium hypo chlorite (50ml, 0.075 mole) was added the reaction mixture was stirred at room temperature for 6 hours.
  • Another mixture of Ferric chloride hexahydrate (100 g, 0.369 mole) and water (500 ml) was mixed with a solution of sodium carbonate (24 g, 0.2264 mole) in water. After stirring for 10-20 minutes, the reaction mixture was mixed with above obtained Dextran reaction mass. To the resulting mixture was added a solution of sodium hydroxide to attain basic pH to 10-13.
  • the obtained mixture was heated at 90-100°C for 2-3 hours and cooled to an ambient temperature and acidified pH-4.0 using Hydrochloric acid. Solution was concentrated to a volume 650 ml and then added with stirring to methanol. The resulting crystalline solid was collected by filtration and washed with methanol. The obtained solids were dried under vacuum to get Iron Dextran.
  • a mixture of dextran grade 5 (Average Molecular weight 5000) (100 g, 0.02 mole) and sodium hydroxide (1.0 g, 0.02 mole) in water was stirred at room temperature for 30 minutes.
  • Sodium hypo chlorite (150ml, 0.225 mole) was added to the mixture.
  • the reaction mixture was stirred at room temperature for 6 hours.
  • Another mixture of Ferric chloride hexahydrate (100 g, 0.369 mole) solution in water (500 ml) was mixed a solution of sodium carbonate (24 g, 0.2264 mole) in water followed by addition of above obtained Dextran reaction mass and the resulting mixture was basified with a solution of sodium hydroxide.
  • Example- 14 To the resulting mixture added a solution of sodium hydroxide to attain basic pH (11-12). The obtained mixture was heated at 90-100°C for 2-3 hours and cooled to an ambient temperature and acidified pH4-5 using Hydrochloric acid. The solution was purified using membrane process (dia filtration). Oxidized dextran (60 g) was added to the purified solution at pH 5 to 6.5 and heated to 70-80° C solution for 2-3 hours. Iron Dextran was isolated as a solid from the reaction mass by spray drying.
  • Example- 14 To the resulting mixture was heated at 90-100°C for 2-3 hours and cooled to an ambient temperature and acidified pH4-5 using Hydrochloric acid. The solution was purified using membrane process (dia filtration). Oxidized dextran (60 g) was added to the purified solution at pH 5 to 6.5 and heated to 70-80° C solution for 2-3 hours. Iron Dextran was isolated as a solid from the reaction mass by spray drying. Example- 14
  • Example- 15 A mixture of dextran -5 (Average Molecular weight 5000) (100 g, 0.02 mole) and sodium hydroxide (0.5 g, 0.01 mole) in water (300 ml) was stirred at room temperature for 30 minutes. Sodium hypo chlorite solution (100 ml, 0.15 mole) was added mixture. The reaction mixture was stirred at room temperature for 6 hours. Another solution of Ferric chloride hexahydrate (100 g, 0.369 mole) in water (500 ml) was mixed with a solution of sodium carbonate (24 g, 0.2264 mole) in water and was stirred for 10-20 minutes. The resulting reaction mass was mixed with the above obtained Dextran reaction mass.
  • the obtained mixture was heated at 90-100°C for 2 hours and cooled to an ambient temperature and acidified to pH 4-5 using Hydrochloric acid.
  • the solution was purified using membrane process (dia filtration) and the purified solution was spray dried to get Iron Dextran powder.
  • Gel Permeation chromatography 106 kda

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Materials Engineering (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Chemistry (AREA)
  • Polymers & Plastics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La présente invention concerne un procédé amélioré pour la préparation de dextrane ferrique et de gluconate ferrique de sodium, qui est reproductible, facile à préparer à l'échelle industrielle, et cohérent dans la plage de poids moléculaire.
PCT/IN2018/050250 2017-04-26 2018-04-25 Procédé amélioré pour la préparation d'un complexe de fer WO2018198135A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN201741014780 2017-04-26
IN201741014780 2017-04-26

Publications (1)

Publication Number Publication Date
WO2018198135A1 true WO2018198135A1 (fr) 2018-11-01

Family

ID=62218028

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IN2018/050250 WO2018198135A1 (fr) 2017-04-26 2018-04-25 Procédé amélioré pour la préparation d'un complexe de fer

Country Status (1)

Country Link
WO (1) WO2018198135A1 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL445709A1 (pl) * 2023-07-29 2025-02-03 Intermag Spółka Z Ograniczoną Odpowiedzialnością Sposób wytwarzania preparatu zawierającego przyswajalne żelazo i zastosowanie preparatu zawierającego przyswajalne żelazo w uprawie roślin

Citations (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US576715A (en) 1897-02-09 Island
US2885393A (en) 1956-02-24 1959-05-05 R K Laros Company Dextran-iron complex and process for making same
WO1997011711A1 (fr) * 1995-09-29 1997-04-03 Luitpold Pharmaceuticals, Inc. Formulations fer-dextran
WO1997017377A1 (fr) * 1995-11-09 1997-05-15 Abbott Laboratories Procede de preparation de fer-dextran cristallin
US5756715A (en) * 1996-11-08 1998-05-26 Abbott Laboratories Process for making crystalline iron dextran
US20030191090A1 (en) * 2002-04-09 2003-10-09 Pharmacosmos Holding A/S Iron dextrin compounds for the treatment of iron deficiency anaemia
WO2005000210A2 (fr) * 2003-05-30 2005-01-06 Chromaceutical Advanced Technologies, Inc. Systhese de complexes fer-saccharide a poids moleculaire eleve
WO2005111052A1 (fr) 2004-05-17 2005-11-24 Cilag Ag Procede de production de complexe de gluconate de fer (iii)
US6977249B1 (en) 1998-11-20 2005-12-20 Pharmacosmos Holding A/S Process for producing an iron-dextran compound, iron-dextran compound produced according to said process, pharmaceutical composition for prophylaxis or treatment of iron-deficiency and use of said compound for the preparation of parenterally administrable pharmaceutical composition
US7179939B2 (en) 2004-03-16 2007-02-20 Navinta Llc Sodium ferric gluconate complexes and method of manufacture thereof

Patent Citations (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US576715A (en) 1897-02-09 Island
US2885393A (en) 1956-02-24 1959-05-05 R K Laros Company Dextran-iron complex and process for making same
WO1997011711A1 (fr) * 1995-09-29 1997-04-03 Luitpold Pharmaceuticals, Inc. Formulations fer-dextran
WO1997017377A1 (fr) * 1995-11-09 1997-05-15 Abbott Laboratories Procede de preparation de fer-dextran cristallin
US5756715A (en) * 1996-11-08 1998-05-26 Abbott Laboratories Process for making crystalline iron dextran
US6977249B1 (en) 1998-11-20 2005-12-20 Pharmacosmos Holding A/S Process for producing an iron-dextran compound, iron-dextran compound produced according to said process, pharmaceutical composition for prophylaxis or treatment of iron-deficiency and use of said compound for the preparation of parenterally administrable pharmaceutical composition
US20030191090A1 (en) * 2002-04-09 2003-10-09 Pharmacosmos Holding A/S Iron dextrin compounds for the treatment of iron deficiency anaemia
WO2005000210A2 (fr) * 2003-05-30 2005-01-06 Chromaceutical Advanced Technologies, Inc. Systhese de complexes fer-saccharide a poids moleculaire eleve
US7179939B2 (en) 2004-03-16 2007-02-20 Navinta Llc Sodium ferric gluconate complexes and method of manufacture thereof
WO2005111052A1 (fr) 2004-05-17 2005-11-24 Cilag Ag Procede de production de complexe de gluconate de fer (iii)

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
JOURNAL OF PHARMACEUTICAL SCIENCES, vol. 99, no. 1, January 2010 (2010-01-01)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL445709A1 (pl) * 2023-07-29 2025-02-03 Intermag Spółka Z Ograniczoną Odpowiedzialnością Sposób wytwarzania preparatu zawierającego przyswajalne żelazo i zastosowanie preparatu zawierającego przyswajalne żelazo w uprawie roślin

Similar Documents

Publication Publication Date Title
US10882813B2 (en) Method for the synthesis of ferric oraganic compounds
JP6799178B2 (ja) ４−メトキシピロール誘導体の中間体の製造方法
US11225565B2 (en) Purification of sugammadex
US20180105609A1 (en) Preparation of water soluble trivalent iron carbohydrate complexes
RU2718920C1 (ru) Способ получения промежуточного соединения для получения производного 4-метоксипиррола
EP0214642A2 (fr) Sels complexes de glucosaminesulfate et leur procédé de préparation
EP3421504A1 (fr) Procédé de fabrication de sugammadex
WO2018198135A1 (fr) Procédé amélioré pour la préparation d'un complexe de fer
EP0392396B1 (fr) Complexes de fer ou d'autres métaux avec des dérivés sulfonés de la chitosane
WO2016181195A1 (fr) Procédé amélioré pour des complexes d'hydrate de carbone et de fer solubles dans l'eau
AU2004319676A1 (en) Method for producing iron (III) gluconate complex
EP1474436B1 (fr) Procede pour la preparation du propionate de fluticasone,notamment de la forme polymorphe 1
JPS6256163B2 (fr)
CN112079902B (zh) 万古霉素衍生物、其中间体、制备方法、组合物及用途
US4076745A (en) Process for calcium salts α-ketocarboxylic acids
EP0073834B1 (fr) Derives de cholesterol solubles dans l'eau
NZ534044A (en) Process for the production of 6.alpha.,9.alpha-difluoro-17.alpha.-(1-oxopropoxy-11.beta.-hydroxy-16.alpha.-methyl-3-oxo-androst-1,4-diene-17.beta.-carbothioic acid
EP2599772B1 (fr) Procédé pour la fabrication de l'acide thiosulfurique d'aminoalkyle
US3471506A (en) Process for preparing 5-chloro-2,3-pyridine diol
JP2003026702A (ja) 水溶性ｎ−飽和脂肪酸アシルキトサン誘導体、及びその製造方法
JPS59138202A (ja) 新規な硫酸化アミノ糖含有多糖及びその製造法
WO2016189549A1 (fr) Nouveau procédé de préparation de sodium d'éthacrynate
CN110922345A (zh) 一种福多司坦的合成方法
JP3035313B2 (ja) ベナノマイシンａ４▲′′′▼‐ｏ‐硫酸エステルの塩類およびそれらの製造法
JPH1095793A (ja) 抗腫瘍性白金錯体カルボプラチンの製造方法

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 18726238

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 18726238

Country of ref document: EP

Kind code of ref document: A1